DOCSLIB.ORG

Boston Patients

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Boston Patients ---------------------------------------------------------------------------------------- MEDIA COVERAGE Boston patients July 2013 – January 2014 ---------------------------------------------------------------------------------------- Summary PART 1: July 2013 Wire Reuters……………………………………………………………………………………………………………… 5 Asian News International (ANI)…………..…………………………………………………………….. 6 Associated Press (AP)………………………………………………………………………………………... 7 Associated Press (AP)………………………………………………………………………………………... 8 Associated Press (AP)………………………………………………………………………………………... 9 Agence France Press (AFP)………………………………………………………………………………… 10 Bloomberg………………………………………………………………………………………………………… 12 United Press International (UPI)……………………………………………………………………….. 14 EFE……………………………………………………………………………………………………………………. 15 Broadcasting NBC-2……………………………………………………………………………………………………………….. 17 BBC…………………………………………………………………………………………………………………… 19 ABC RADIO………………………………………………………………………………………………………… 22 ABC RADIO………………………………………………………………………………………………………… 23 NBC…………………………………………………………………………………………………………………… 24 ForexTV…………………………………………………………………………………………………………….. 27 CBN…………………………………………………………………………………………………………………… 28 CBS……………………………………………………………………………………………………………………. 29 Al Jazeera………………………………………………………………………………………………………….. 31 CNN………………………………………………………………………………………………………………….. 32 NBC…………………………………………………………………………………………………………………… 35 Newspapers, magazines and blogs The New York Times…………………………………………………………………………………………. 37 The Wall Street Journal…………………………………………………………………………………….. 40 Financial Times…………………………………………………………………………………………………. 41 The Guardian…………………………………………………………………………………………………….. 43 The Times…………………………………………………………………………………………………………. 45 The Independent………………………………………………………………………………………………. 46 The Boston Globe……………………………………………………………………………………………… 49 Le Figaro………………………………………..…………………………………………………………………. 51 Forbes…………………………………………………………………………………………………………….… 52 Metro……………………………………………………………………………………………………………….. 54 Science Now……………………………………………………………………………………………………… 55 New Scientist……………………………………………………………………………………………………. 57 New Scientist……………………………………………………………………………………………………. 59 The Washington Post………………………………………………………………………………………… 61 El Mundo………………………………………………………………………………………………………….. 63 El País……………………………………………………………………………………………………………….. 64 MedPage Today………………………………………………………………………………………………… 66 Huffington Post…………………………………………………………………………………………………. 68 The Week………………………………………………………………………………………………………….. 70 2 The Scientist……………………………………………………………………………………………………… 71 Europaikos Notos……………………………………………………………………………………………… 72 The Lancet………………………………………………………………………………………………………… 73 Nature………………………………………………………………………………………………………………. 74 HIVandHEPATITIS.com………………………………………………………………………………………. 76 HIVandHEPATITIS.com………………………………………………………………………………………. 79 AIDSMAP…………………………………………………………………………………………………………… 80 Physicians Briefing…………………………………………………………………………………………….. 83 PART 2 : December 2013 / January 2014 Wire Reuters……………………………………………………………………………………………………………… 85 Bloomberg….…………………………………………………………………………………………………….. 87 United Press International (UPI)……….………………………………………………………………. 88 Europa Press…………………………………………………………………………………………………….. 90 Agenzia Italia (AGI)……………………………………………………………………………………………. 91 Broadcasting NPR…………………………………………………………………………………………………………………… 92 NBC…………………………………………………………………………………………………………………… 94 CBS……………………………………………………………………………………………………………………. 96 CNN…………………………………………………………………………………………………………………… 98 Newspapers, magazines and blogs The New York Times…………………………………………………………………………………………. 101 The Boston Globe……………………………………………………………………………………………… 103 El País……………………………………………………………………………………………………………….. 106 El País……………………………………………………………………………………………………………….. 107 El Día.……………………………………………………………………………………………………………….. 109 Libération………………………………………………………………………………………………………….. 111 La Repubblica…….……………………………………………………………………………………………… 112 Daily News……...……………………………..…………………………………………………………………. 113 HIVandHEPATITIS.com………………………………………………………………………………………. 115 3 Part 1: July 2013 4 Wire Stem-cell therapy wipes out HIV in two patients By Ben Hirschler. LONDON Wed Jul 3, 2013 7:53am EDT (Reuters) - Two men with HIV have been off AIDS drugs for several months after receiving stem-cell transplants for cancer that appear to have cleared the virus from their bodies, researchers reported on Wednesday. Both patients, who were treated in Boston and had been on long-term drug therapy to control their HIV, received stem-cell transplants after developing lymphoma, a type of blood cancer. Since the transplants, doctors have been unable to find any evidence of HIV infection, Timothy Henrich of Harvard Medical School and Brigham and Women's Hospital in Boston told an International AIDS Society conference in Kuala Lumpur. While it is too early to say for sure that the virus has disappeared from their bodies altogether, one patient has now been off antiretroviral drug treatment for 15 weeks and the other for seven weeks. Last July Henrich first reported that the two men had undetectable levels of HIV in their blood after their stem- cell treatment, but at that time they were still taking medicines to suppress HIV. Using stem-cell therapy is not seen as a viable option for widespread use, since it is extremely expensive, but the latest cases could open new avenues for fighting the disease, which infects about 34 million people worldwide. The latest cases resemble that of Timothy Ray Brown, known as "the Berlin patient", who became the first person to be cured of HIV after receiving a bone marrow transplant for leukaemia in 2007. There are, however, important differences. While Brown's doctor used stem cells from a donor with a rare genetic mutation, known as CCR5 delta 32, which renders people virtually resistant to HIV, the two Boston patients received cells without this mutation. "Dr. Henrich is charting new territory in HIV eradication research," Kevin Robert Frost, chief executive officer of the Foundation for AIDS Research, which funded the study, said in a statement. Scientific advances since HIV was first discovered more than 30 years ago mean the virus is no longer a death sentence and the latest antiretroviral AIDS drugs can control the virus for decades. But many people still do not get therapy early enough, prompting the World Health Organization to call for faster roll-out of medicines after patients test positive. Indian generics companies are leading suppliers of HIV drugs to Africa and to many other poor countries. Major Western HIV drugmakers include Gilead Sciences, Johnson & Johnson and ViiV Healthcare, which is majority-owned by GlaxoSmithKline. Source: http://www.reuters.com/article/2013/07/03/us-hiv-stemcells-idUSBRE9620IL20130703 5 7/3/13 - Hopes soar for HIV cure after 2 US men cured of virus [Asian News International] Melbourne, July 3 (ANI): Two American men are believed to have overcome HIV, boosting hopes as they join a handful of people who are said to have been cured of the virus, to find a wider cure. Doctors from the Brigham and Women's Hospital in Boston announced on Wednesday night that two previously HIV-positive patients no longer had detectable virus levels in their blood or tissue after having bone marrow stem-cell transplants to treat cancer between two and four years ago, the Age reported. Remarkably, the two men - a young man and another in middle age - have also remained clear of the virus after stopping anti-retroviral therapy eight and 15 weeks ago. When most HIV-positive people stop taking treatment, the virus becomes active again within four to eight weeks. The Boston pair look set to join a Mississippi toddler believed to have been cured of HIV by intense treatment 30 hours after birth and Timothy Ray Brown, the "Berlin patient" famously cured of HIV six years ago after having a similar bone marrow transplant to treat cancer in Germany. However, there is a key difference between the Berlin and Boston patients that could advance research towards a cure for HIV. Brown received a transplant from a donor with an unusual gene mutation that resists HIV whereas the Boston patients received transplants from donors with no known resistance to the disease. Timothy Henrich and Daniel Kuritzkes, the doctors managing the Boston patients, told an HIV conference in Malaysia that this suggested the process of stem-cell transplantation was responsible for their suspected remission. In particular, they believe a common complication of transplantation, graft-versus-host disease, could be at play because it involves newly transplanted donor cells attacking the transplant recipient's body. The doctors said although it was too early to say whether their patients had been cured permanently, repeated tests of large volumes of cells, plasma and tissue had found no sign of the virus. (ANI) Source: http://www.pharmacychoice.com/News/article.cfm?Article_ID=1073362 6 Células madre parecen ayudar a pacientes con sida Por EILEEN NG - 07/03/2013 KUALA LUMPUR, Malasia - Dos pacientes en Estados Unidos infectados con el virus de inmunodeficiencia humana (VIH) y que fueron sometidos a trasplante de médula ósea debido al cáncer dejaron de tomar medicinas antirretrovirales y siguen sin mostrar indicios perceptibles del virus, dijeron los investigadores el miércoles. Los investigadores de la Universidad de Harvard insistieron que es demasiado pronto para afirmar que los hombres han sido curados, pero agregaron que es un indicio esperanzador que el virus no haya reaparecido en su sangre meses después de haber concluido su tratamiento con fármacos. La
Load more

Recommended publications
  • Charting a Path Along the Continuum of PMTCT of HIV-1, to Elimination, and Finally to Eradication
    EDITORIAL Charting a path along the continuum of PMTCT of HIV-1, to elimination, and finally to eradication In this editorial we traverse the continuum of We stress that much of the hard scientific data on prevention transmission of HIV-1 from mothers to children to and elimination are already available; what is required are health highlight the biomedical history of this problem. service refinements. Eradication demands many more basic science Treatment has progressed from prevention with experiments to confirm the results indicating ‘cure’ in the Mississippi antiretrovirals (ARVs) through to a broader set of baby, and to increase our understanding of the biology of latency interventions, including various breastfeeding options and other health and destruction of the replicative capacity of the virus. We need system improvements, that have increased the possibility of eliminating more information on the cellular and molecular environment of mother-to-child-transmission (MTCT) of HIV. At the far end of the the CD4+ memory cells, and specific sites that harbour the virus. continuum, the spectacular findings in the case of the Mississippi Among the prerequisites for eradication are public health studies ‘cured’ baby indicate that eradication is possible. to enable SA to scale up facilities and personnel for very early HIV infections in children are overwhelmingly due to MTCT,[1] intra- diagnosis and treatment. uterine infections accounting for 10 - 25% of cases and intrapartum infections and those through breastfeeding for 35 - 40%. High- and Prevention middle-income countries have had considerable success in preventing Numerous reviews of trials undertaken to prevent MTCT have new HIV infections in children.
    [Show full text]
  • Are We Standing in Our Own Way on the Path to a Cure for HIV/AIDS
    PROFILE Are we standing in our own way on the path to a cure for HIV/AIDS lthough there are many reasons to celebrate the life-extending benefits from antiretroviral Atherapeutics (ART) for HIV/AIDS and the ability to chronically manage patients’ disease for decades, the majority of people around the world living with the virus do not have access to ART and those that do, have over decades developed life-threatening side effects. Our inability to identify a cure to HIV lies not only in the as-of- yet failure of the medical research community to identify and develop appropriate means of ridding the body of the virus but also government and industrial policies that promote public opinion exclusively focused on chronic management scenarios instead of broadly exploring innovation for cure. “An inconvenient truth” (Davis Guggenheim) mates of the magnitude of the global forced government policy for early epidemic. As the majority of Ameri - and expanded access to experimental There are approximately 37 million cans are not rountinely tested for HIV, drugs, the medical community and people living with HIV and 39 million the virus can go years without being society are struggling with the fact have died of AIDS-related diseases diagnosed in an HIV positive person. that we are barely managing the HIV since the start of the epidemic in 1981. With these statistics it is no wonder epidemic and AIDS crisis. For years we As of March 2015, only 15 million that every day an estimated 5,600 have been locked into thinking of people have access to treatments for people globally become newly infected solutions in terms of a chronic disease HIV.
    [Show full text]
  • NOMINEES for the 32Nd ANNUAL NEWS & DOCUMENTARY EMMY
    NOMINEES FOR THE 32 nd ANNUAL NEWS & DOCUMENTARY EMMY ® AWARDS ANNOUNCED BY THE NATIONAL ACADEMY OF TELEVISION ARTS & SCIENCES Winners to be announced on September 26th at Frederick P. Rose Hall, Home of Jazz at Lincoln Center Larry King to Receive Lifetime Achievement Award New York, N.Y. – July 18, 2011 (revised 8.24.11) – Nominations for the 32nd Annual News and Documentary Emmy ® Awards were announced today by the National Academy of Television Arts & Sciences (NATAS). The News & Documentary Emmy® Awards will be presented on Monday, September 26 at a ceremony at Frederick P. Rose Hall, Home of Jazz at Lincoln Center, located in the Time Warner Center in New York City. The event will be attended by more than 1,000 television and news media industry executives, news and documentary producers and journalists. Emmy ® Awards will be presented in 42 categories, including Breaking News, Investigative Reporting, Outstanding Interview, and Best Documentary, among others. This year’s prestigious Lifetime Achievement Award will be given to broadcasting legend and cable news icon Larry King. “Larry King is one of the most notable figures in the history of cable news, and the National Academy of Television Arts and Sciences is delighted to present him with this year’s lifetime achievement award,” said Malachy Wienges, Chairman, NATAS. “Over the course of his career Larry King has interviewed an enormous number of public figures on a remarkable range of topics. In his 25 years at CNN he helped build an audience for cable news and hosted more than a few history making broadcasts.
    [Show full text]
  • Download The
    WHAT ABOUT CONDOMS? CONFERENCE UPDATE: T HE CROI REPORT WHY I RIDE: Ou T AND OPEN IN THE RIDE FOR AIDS CHICAGO POSITIVELY AWARE THE HIV TREATMENT JOURNAL OF TEST POSITIVE AWARE NETWORK MAY+JUNE 2015 T HE BIGGES CHANGES IN 20 YEARS ARE COMING REIn THINK NG HIV NEW APPROACHES TO TREATMENT n CHASING THE CURE n 3D animation OF HIV Client Name: GSK/Triumeq Healthcare This advertisement prepared by: Product: Triumeq Havas Worldwide Job Number: 200 Hudson Street 65013 Filename 65013_58522_M02_DTR045R0_CouchSpread_ Last Modified 1-14-2015 12:41 PM User / PrevUs- Derrick.Edwin / Aileen.Boyce Client GSK Triumeq Art Director M. Culbreth Bleed 16.25” x 10.75” Path Premedia:Volumes:Premedia:Pre- CMYK press:65013_58522:Final:Pre- 0000065013_0000058522_M02_DTR045R0_FCAD – Positively Aware New York, New York 10013 Create 1-14-2015 10:42 AM Artist Kerry Trim 16” x 10.5” press:65013_58522_M02_DTR045R0_ CouchSpread_FCAD-for PREPRESS. Proof Caption: “I have the courage to start HIV…” (Man on Couch) 3 Traffic R. Rodriguez Saftey 15” x 10” indd Fonts Helvetica Neue LT Std (75 Bold, 77 Bold Condensed, 57 Condensed, 55 Roman, 47 Light Condensed, 67 Medium Condensed, 47 Light Condensed Oblique; OpenType), Minion Pro (Regular; OpenType), TT Slug Media: 4/C Magazine Spread + PBW +PBW + ½ PBW AD: M. Culbreth OTF (Regular; OpenType) PAR # DTR045R0 AE: M. Halle Art TRIU_58522_01_CeasarCouchAd_SW_V6_HR.tif (Premedia:Prepress:65013_58522:Original:1.14.15:0000065013_0000058522_M02_DTR045R0_CouchSpread_FCAD Folder:Links:TRIU_58522_01_CeasarCouch- Ad_SW_V6_HR.tif), ViiVHCcmyk.ai (Premedia:Prepress:65013_58522:Original:1.14.15:0000065013_0000058522_M02_DTR045R0_CouchSpread_FCAD Folder:Links:ViiVHCcmyk.ai), Triumeq_US_CMYK_Reg_NEW. Prod: I. Waugh ai (Premedia:Prepress:65013_58522:Original:1.14.15:0000065013_0000058522_M02_DTR045R0_CouchSpread_FCAD Folder:Links:Triumeq_US_CMYK_Reg_NEW.ai), TRIU_58522_02_ItsTimeLogo_SW_V1_130_ B: 16.25” x 10.75” T: 16” x 10.5” Bill Studio Labor OOP to: 0000065013 S: 15” x 10” Gutter Safety = 1” B:16.25” T:16” S:15” TRIUMEQ is a once-a-day pill used to treat HIV-1.
    [Show full text]
  • Protecting Colleges & Universities Against Real Losses in a Virtual World, 33 J. Marshall J. Info. Tech. & Privacy L. 10
    The John Marshall Journal of Information Technology & Privacy Law Volume 33 | Issue 2 Article 3 2017 Protecting Colleges & Universities Against Real Losses in a Virtual World, 33 J. Marshall J. Info. Tech. & Privacy L. 101 (2017) Gregory Demers Seth Harrington Mark Cianci Nicholas Green Follow this and additional works at: https://repository.jmls.edu/jitpl Part of the Computer Law Commons, Education Law Commons, Internet Law Commons, Privacy Law Commons, and the Science and Technology Law Commons Recommended Citation Gregory Demers, Seth Harrington, Mark Cianci, & Nicholas Green, Protecting Colleges & Universities Against Real Losses in a Virtual World, 33 J. Marshall J. Info. Tech. & Privacy L. 101 (2017) https://repository.jmls.edu/jitpl/vol33/iss2/3 This Article is brought to you for free and open access by The oJ hn Marshall Institutional Repository. It has been accepted for inclusion in The oJ hn Marshall Journal of Information Technology & Privacy Law by an authorized administrator of The oJ hn Marshall Institutional Repository. 2017] Protecting Colleges & Universities 101 ARTICLE PROTECTING COLLEGES & UNIVERSITIES AGAINST REAL LOSSES IN A VIRTUAL WORLD GREGORY L. DEMERS, SETH C. HARRINGTON, MARK A. CIANCI, AND NICHOLAS R. GREEN, – ROPES & GRAY LLP * SUMMARY: Colleges and universities are prime targets for cyberattacks. Au- thors Gregory L. Demers, Seth C. Harrington, Mark A. Cianci, and Nicholas R. Green explore emerging data security risks and litigation trends on college campuses, and offer ways to manage these risks through a comprehensive insurance plan. Given the increasing variety and complexity of plans available, it is incumbent upon universities to regularly reassess the coverage afforded by their existing policies.
    [Show full text]
  • HIV/AIDS and Cancer Cure: Is It the Same Battle?
    HIV/AIDS and Cancer cure: Is it the same battle? Monsef Benkirane Molecular Virology Laboratory [email protected] IAS HIV Cure & Cancer Forum Paris, France www.iasociety.org Dynamic of imatinib-treated Chronic Myeloid Leukemia Mature cancer cells Highly divinding Cancer Stem cells www.iasociety.org Persistence and resistance are theBarriers to Cure HIV/AIDS Cancer Latent provirus Quiescent / slow-cycling Quiescent/ slow-cycling Long-lived Long-lived Indefinite proliferative potential Non sensitive to ART Enhanced repair capacity Not visible to the immune system highly resistant to DNA HIV-specific CD8 T cell response damage/Tolerance decreases with cART Enhanced checkpoint kinase expression drug efflux transporter Renewed by dedifferentiation of proliferating cancer HIV/AIDS and cancer are Residual diseases Although their molecular bases are different, similar cure strategies are being developed www.iasociety.org which cure and how to achieve it? Two main strategies are being pursued Eradication, which will require a complete elimination of infected cells, for which the Berlin patient represents a proof of concept. Considering the Boston patients, eradication will require elimination of HIV infected cells and replacement with HIV resistant cells. Remission: HIV controllers and the VISCONTI patients suggest that remission is achievable. This strategy should include monitoring of inflammatory and procoagulant indices. – Find and diminish size of the reservoir (LRAs, bNAbs, CAR-T cell) – Reduce seeding of latent pool with early/more ART – Reverse latency (LRAs, TLR7) – Increase HIV-specific immune function (vaccines or anti PD-L1) – Reduce immune activation – Gene therapy targeting the virus and the host – Allogeneic stem cell transplantation Combination therapy may be necessary While proof-of-concepts are there, we still have to gain important knowledge to achieve HIV eradication or remission Strategies to eradicate latent reservoirs.
    [Show full text]
  • Cybersecurity for Connected Cars Exploring Risks in 5G, Cloud, and Other Connected Technologies
    Cybersecurity for Connected Cars Exploring Risks in 5G, Cloud, and Other Connected Technologies Numaan Huq, Craig Gibson, Vladimir Kropotov, Rainer Vosseler TREND MICRO LEGAL DISCLAIMER The information provided herein is for general information Contents and educational purposes only. It is not intended and should not be construed to constitute legal advice. The information contained herein may not be applicable to all situations and may not reflect the most current situation. 4 Nothing contained herein should be relied on or acted upon without the benefit of legal advice based on the particular facts and circumstances presented and nothing The Concept of Connected Cars herein should be construed otherwise. Trend Micro reserves the right to modify the contents of this document at any time without prior notice. 7 Translations of any material into other languages are intended solely as a convenience. Translation accuracy is not guaranteed nor implied. If any questions arise Research on Remote Vehicle related to the accuracy of a translation, please refer to Attacks the original language official version of the document. Any discrepancies or differences created in the translation are not binding and have no legal effect for compliance or enforcement purposes. 13 Although Trend Micro uses reasonable efforts to include Cybersecurity Risks of Connected accurate and up-to-date information herein, Trend Micro makes no warranties or representations of any kind as Cars to its accuracy, currency, or completeness. You agree that access to and use of and reliance on this document and the content thereof is at your own risk. Trend Micro disclaims all warranties of any kind, express or implied.
    [Show full text]
  • Identity Theft: the Aftermath 2017 1
    Identity Theft: The Aftermath 2017 1 PRESIDENT & CEO IDENTITY THEFT RESOURCE CENTER (ITRC) Eva Velasquez CONTRIBUTORS Eva Velasquez, ITRC President & CEO Julie Ferguson, ITRC Board of Directors Chair, Industry Expert Matt Cullina, ITRC Board of Directors Vice Chair, Industry Expert Terri Beck, ITRC Board of Directors, Secretary, Industry Expert Paul Bond, ITRC Board of Directors, Industry Expert Matthew Donahue, ITRC Board of Directors, Industry Expert Susan Grant, ITRC Board of Directors, Industry Expert Stew Roberts, ITRC Board of Directors, Industry Expert Paige Schaffer, ITRC Board of Directors, Industry Expert Robert Siciliano, ITRC Board of Directors, Industry Expert Mona Terry, ITRC Karen Barney, ITRC Kelly Dwyer, ITRC Alex Hamilton, ITRC CONTACT Kelly Dwyer Director of Communications [email protected] (858) 634-6385 Identity Theft: The Aftermath 2017 2 TABLE OF CONTENTS Executive Summary and Highlights ..................................................................................................... 4 Introduction / Methodology ................................................................................................................... 6 Key Findings A. Victims’ actions following identity theft .............................................................................. 7 B. Significant number of ways identity theft impacts victims ................................................ 8 C. Victims’ relationships with others ........................................................................................ 9 D.
    [Show full text]
  • Study Protocol
    RIVER Protocol Version 5.0 20-Oct-2016 GENERAL INFORMATION This document was constructed using the MRC CTU Protocol Template Version 3.0. The MRC CTU endorses the Standard Protocol Items: Recommendations For Interventional Trials (SPIRIT) initiative. It describes the RIVER trial, co-ordinated by the Medical Research Council (MRC) Clinical Trials Unit at UCL (herein referred to as MRC CTU), and provides information about procedures for entering participants into it. The protocol should not be used as an aide-memoire or guide for the treatment of other participants. Every care has been taken in drafting this protocol, but corrections or amendments may be necessary. These will be circulated to the registered investigators in the trial, but sites entering participants for the first time are advised to contact RIVER Co-ordinating Centre at, MRC CTU, to confirm they have the most up-to-date version. COMPLIANCE The trial will be conducted in compliance with the approved protocol, the Declaration of Helsinki 1996, the principles of Good Clinical Practice (GCP), Commission Directive 2005/28/EC with the implementation in national legislation in the UK by Statutory Instrument 2004/1031 and subsequent amendments, the UK Data Protection Act (DPA number: Z6364106), and the National Health Service (NHS) Research Governance Framework for Health and Social Care (RGF). SPONSOR Imperial College London is the trial sponsor and has delegated responsibility for the overall management of the RIVER trial to the MRC CTU (RIVER Co-ordinating Centre). Queries relating to Imperial sponsorship of this trial should be addressed to the chief investigator via the Imperial Joint Research Compliance Office.
    [Show full text]
  • Growing up to Meet the Times
    WWW.MIREALTORS.COM 13 SEPTEMBER 20 SEPTEMBER GROWING UP TO meET THE TImeS PLUS: The Myth of Multi-tasking Working To Get Listings Green Renovations The EMD Hot Potato Protection from Scams Volume 12 | Number 5 Volume Who Says You Can’t Have It All? Free yourself, and discover an innovative, smart and portable way to increase productivity and efficiency in your real estate business with EXIT Realty’s Total Office Resource Center. Your business. Your life. All in one place. CONNECT WITH ME TO LEARN MORE Craig Witt, President - North Central Division 1-877-669-3948, [email protected] www.exitrealty.com/michigan Forget game-changer, let’s talk about life-changer! EXITRealtyMichigan_September2013.indd 2 7/4/2013 1:11:07 PM 09.13 Who Says You Can’t Have It All? OF TABLE Features 07 Keeping Scammers at Bay Here are a lot of ways to protect yourself by Robert Siciliano 10 How Green is Your Renovation Project? CONTENTS Smart makeovers can save you money in the long run by Brent Wayne COVER STORY 14 Michigan’s MLSs Coming of Age Changing with the times helps everybody 18 It is Time to Forsake Multi-tasking Often the more you do, the less you accomplish by Jeff Davidson 21 Earning the Business! Give customers good reasons to hire you by Marcus Wally 24 Appraisers Must Understand Michigan’s Appraisal License Laws There’s more to them than meets the eye by Micheal R. Lohmeier Departments 02 President’s Report Keys to a commercial lease by Bill Milliken 04 Capitol Report Seeing the trees for the forest Free yourself, and discover an innovative, smart and by Brad Ward 26 Legal Lines portable way to increase productivity and efficiency in your real estate EMDs: It never stops by Gregory L.
    [Show full text]
  • What Will It Take to Cure HIV?
    IAS–USA Topics in Antiviral Medicine Perspective What Will It Take to Cure HIV? Investigational strategies to attempt HIV cure or remission include very detectable virus during 3 years of treat- early initiation of antiretroviral therapy to limit the latent HIV reservoir and ment but exhibited viral rebound 2 preinfection vaccination. In the setting of viral suppression, strategies include weeks to 3 weeks after stopping treat- reactivation of latently infected cells (eg, through “shock” therapy with ment. Similarly, an HIV-infected baby histone deacetylase inhibitors or other agents); use of broadly neutralizing in Milan began antiretroviral treatment antibodies, therapeutic vaccines, immunotoxins, or other immune-based 12 hours after birth and had no detect- therapies to kill latently infected cells; and gene editing to induce target able virus for 3 years while receiving cell resistance (eg, by eliminating the CC chemokine receptor 5 [CCR5] treatment but exhibited viral rebound 2 coreceptor). Improved ability to detect and quantify very low levels of virus weeks to 3 weeks after stopping treat- is needed. This article summarizes a presentation by Jintanat Ananworanich, ment.5-9 MD, PhD, at the IAS–USA continuing education program held in New York, In general, it is believed that earlier New York, in October 2014. initiation of antiretroviral therapy and the longer it is maintained improve the Keywords: HIV, cure, remission, viral reservoir, latent infection chance of limiting the viral reservoir and achieving HIV remission. How- ever, among the infants who eventually HIV cure research currently focuses 7 months, respectively, after receiv- exhibited rebound after stopping anti- on 2 goals: complete eradication of ing bone marrow transplantation with retroviral therapy, time to viral rebound HIV from the body and HIV remission.
    [Show full text]
  • Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection
    Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection Developed by the HHS Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV—A Working Group of the Office of AIDS Research Advisory Council (OARAC) How to Cite the Pediatric Guidelines: Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Available at http://aidsinfo.nih.gov/content- files/lvguidelines/pediatricguidelines.pdf. Accessed (insert date) [include page numbers, table number, etc. if applicable] Use of antiretrovirals in pediatric patients is evolving rapidly. These guidelines are updated regularly to provide current information.The most recent information is available at http://aidsinfo.nih.gov. What’s New in the Pediatric Guidelines (Last updated April 14, 2020; last reviewed April 14, 2020) The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) has reviewed previous versions of the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection and revised the text and references. Key updates are summarized below. April 14, 2020 When to Initiate Therapy in Antiretroviral-Naive Children • The Panel now recommends rapid initiation of antiretroviral therapy (ART) for all children, not just those aged <1 year. Rapid initiation is defined as initiating therapy immediately or within days of HIV diagnosis. • Because the Panel no longer makes recommendations about when to initiate ART based on a child’s age (either <1 year of age or ≥1 year of age), Table A has been deleted and the data that support rapid initiation have been grouped by outcome (i.e., survival and health benefits, neurodevelopmental benefits, immune benefits, and viral reservoirs and viral suppression).
    [Show full text]